Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. The technical chart shows consolidation. See ...

To date, a number of clinical trials have shown weight regain after discontinuing GLP-1 drugs. In the STEP 1 trial extension, ...

Innovation in the industry is at its peak, with spaces like weight loss/obesity ... both Eli Lilly’s tirzepatide drugs (Mounjaro and Zepbound) and Novo Nordisk’s semaglutide drugs (Ozempic ...

The Medicine Foundry, which is expected to create 400 jobs, will be situated in the LEAP Research and Innovation District in ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 569.58% and ...

New public and private entrants are emerging to challenge the leading positions of Novo Nordisk NVO and Eli Lilly LLY in a ...

Novo and Lilly lead the weight-loss drugs market with injections Wegovy and Zepbound. But numerous companies ... MarketSurge chart analysis shows. Follow Allison Gatlin on X, the platform formerly ...

The group of $1 trillion market cap stocks is tiny, and pharmaceutical giant Eli Lilly (NYSE: LLY) isn't a member yet, though ...